share_log

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q:季报延迟披露公告
美股sec公告 ·  05/15 17:10
Moomoo AI 已提取核心信息
bluebird bio, Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024. The delay is attributed to the ongoing restatement of the company's financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. Consequently, the company is unable to meet the May 15, 2024, filing deadline for the Quarterly Report. The restatement process has uncovered errors related to the accounting of embedded leases and the treatment of non-lease components in lease agreements with contract manufacturing organizations. Despite these issues, bluebird bio does not anticipate any impact on its cash position or revenue from these errors. The company has also indicated that there will be significant...Show More
bluebird bio, Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024. The delay is attributed to the ongoing restatement of the company's financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. Consequently, the company is unable to meet the May 15, 2024, filing deadline for the Quarterly Report. The restatement process has uncovered errors related to the accounting of embedded leases and the treatment of non-lease components in lease agreements with contract manufacturing organizations. Despite these issues, bluebird bio does not anticipate any impact on its cash position or revenue from these errors. The company has also indicated that there will be significant changes in its results of operations for the quarter ended March 31, 2024, compared to the same period in 2023, but it is currently unable to provide an estimate of these changes. The notification filed with the SEC also includes forward-looking statements and acknowledges that the company's 2023 Form 10-K has not yet been filed.
蓝鸟生物公司宣布延迟提交截至2024年3月31日的第一季度10-Q表季度报告。延迟归因于公司持续重报截至2022年12月31日的年度以及2022年和2023年前三个季度的财务报表。因此,该公司无法在2024年5月15日提交季度报告的截止日期之前提交。重报过程发现了与嵌入式租赁会计以及与合同制造组织签订的租赁协议中对非租赁部分的处理有关的错误。尽管存在这些问题,但bluebird bio预计这些错误不会对其现金状况或收入产生任何影响。该公司还表示,与2023年同期相比,截至2024年3月31日的季度经营业绩将发生重大变化,但目前无法提供这些变化的估计。向美国证券交易委员会提交的通知还包括前瞻性陈述,并承认该公司尚未提交2023年10-K表格。
蓝鸟生物公司宣布延迟提交截至2024年3月31日的第一季度10-Q表季度报告。延迟归因于公司持续重报截至2022年12月31日的年度以及2022年和2023年前三个季度的财务报表。因此,该公司无法在2024年5月15日提交季度报告的截止日期之前提交。重报过程发现了与嵌入式租赁会计以及与合同制造组织签订的租赁协议中对非租赁部分的处理有关的错误。尽管存在这些问题,但bluebird bio预计这些错误不会对其现金状况或收入产生任何影响。该公司还表示,与2023年同期相比,截至2024年3月31日的季度经营业绩将发生重大变化,但目前无法提供这些变化的估计。向美国证券交易委员会提交的通知还包括前瞻性陈述,并承认该公司尚未提交2023年10-K表格。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息